Dr. Rekdal is Co-founder of and served as CEO during the first 4 years of Lytix Biopharma’s formation.

After that he served as CSO and Head of R&D before he again was promoted to the position of CEO in 2019. Rekdal`s research background is within tumor immunology and his field of expertise is anticancer molecules derived from host defense peptides. Dr. Rekdal commenced his PhD on cytokines and tumor immunology in 1996, and his postdoctoral work forms the basis of Lytix Biopharma’s technology peptide platform.

Dr. Rekdal has been instrumental in establishing collaboration with several distinguished researchers and institutions and is regularly invited to give plenary lectures at international oncology, industry and partnering conferences.

Mr. Breistein has extensive experience as an auditor and consultant. Prior to joining Lytix in 2017, he worked at PwC advising public and private companies across multiple industry sectors in capital market transactions, financing and listing processes.

Mr. Breistein is a state authorized public accountant, and holds a Masters in Applied Economics and Finance from Copenhagen Business School, as well as a Masters in Professional Accountancy from BI Norwegian School of Management.

Dr. Sveinbjørnsson achieved his doctorate at the Medical Faculty of the University of Tromsø in 1998, with a focus on mechanisms and mediators behind immunomodulation of experimental tumors. Since then, Dr. Sveinbjørnsson has gained a broad experience of preclinical oncology at the University of Tromsø and Karolinska Institutet Stockholm. 

Dr. Sveinbjørnsson has been involved in the research activities of Lytix Biopharma since the beginning, and has most recently led the Company’s research activities as Chief Scientific Officer.

Dr. Mette Husbyn brings over 16 years of experience at GE Healthcare, where she held various scientific and managerial roles covering all aspects of CMC, from pre-clinical and early clinical phases to commercial products. 

Following her tenure at GE, Dr. Husbyn served as Head of CMC at Lytix Biopharma from 2012 to 2017, where she oversaw all CMC activities and established robust processes to enhance drug development. 

Most recently, she held the position of Head of CMC and CTO at Nykode Therapeutics, leading a team of 32 professionals focused on strategic partner selection, process development, and regulatory interactions across the US and Europe.

Dr. Husbyn earned her doctorate from the Medical Faculty of the University of Oslo in 2003, specializing in peptide chemistry.

Mr. Meadows has more than 25 years experience in biopharmaceutical strategy and business development leadership roles.  Most recently, Mr. Meadows served as CBO at OncoOne, where he defined the company's overall business strategy and oversaw all aspects of business development and partnering, including deal execution. He has also held senior-level positions in business development, commercial strategy and global marketing at Regeneron, Bristol Myers Squibb, Biogen and Johnson and Johnson. While at AVEO Oncology and Baxalta/Shire, he co-led multiple transactions each worth over $1 billion, transforming these oncology franchises.

He holds a Masters in Business Administration from Babson College and a Bachelors in Science in Finance from the University of Richmond. 

Ahmed senior executive experience in the biotechnology industries spans more than 30 years in Europe, China, and the US. Until recently, Ahmed held senior executive positions in biotech SMEs and Mid-Cap companies such as Trinomab Biotech, Angine Biotech, and ProductLife Group.  He also founded and served as CEO of Vaxeal Holding Group and SEDAC Therapeutics, companies specialized in immunotherapy, with both successful exits. He was President of the European Biopharmaceutical Enterprises (EBE, integrated into EFPIA), and Board Member of Vaccines Europe. Ahmed has an extensive experience in large private and public fund raising, M&A, and licensing.

Ahmed holds a PhD in biology and an MBA from the University of New Hamsphire, US.